- Home
- AAME vs IMA Comparison
AAME vs IMA Comparison
Compare AAME & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AAME | IMA |
|---|---|---|
| Founded | 1968 | 2019 |
| Country | United States | United States |
| Employees | N/A | 17 |
| Industry | Life Insurance | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.2M | 66.3M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | AAME | IMA |
|---|---|---|
| Price | $2.20 | $5.84 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 4.5K | ★ 42.8K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $188,227,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.00 | ★ N/A |
| Revenue Growth | ★ 0.77 | N/A |
| 52 Week Low | $1.65 | $3.94 |
| 52 Week High | $3.71 | $17.50 |
Technical Indicators
Market Signals| Indicator | AAME | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 37.59 | 55.70 |
| Support Level | $2.15 | $5.23 |
| Resistance Level | $3.16 | $6.21 |
| Average True Range (ATR) | 0.09 | 0.37 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 2.68 | 91.40 |
Price Performance
Historical ComparisonAbout AAME Atlantic American Corporation
Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.